CorMedix (CRMD) vs Oculis (OCS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
CorMedix (CRMD) has outperformed Oculis (OCS) over the past year, losing 35.0% versus a loss of 56.4%. Over five years, CRMD leads with a +47.9% price change compared with -11.8% for OCS. CorMedix is the larger company by market cap ($570.6 million vs $533.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRMD | OCS |
|---|---|---|
| Share price | $7.32 | $8.66 |
| Market cap | $570.55M | $533.35M |
| 1-day change | +0.55% | +1.88% |
| YTD return | -37.06% | -56.63% |
| 1-year return | -35.05% | -56.42% |
| 5-year return | +47.88% | -11.81% |
| P/E ratio (TTM) | 3.57 | — |
| Forward P/E | 20.91 | — |
| EPS (TTM) | $2.05 | $-1.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.02 | $34.48 |
| 52-week low | $6.13 | $8.30 |
| Distance from 52-week high | -43.78% | -74.88% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +109.43% | +321.36% |
| Average volume | 1.06M | 257.00K |
| Shares outstanding | 77.94M | 61.59M |
| Employees | 191 | 60 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRMD has outperformed OCS by 21.4 percentage points over the past year.
About CorMedix
CRMD stock →CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
Health Care · Biotechnology: Pharmaceutical Preparations · 191 employees
About Oculis
OCS stock →Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees
CRMD vs OCS FAQ
Which is bigger, CorMedix or Oculis?
CorMedix (CRMD) is larger, with a market capitalization of $570.55M compared with $533.35M for Oculis (OCS).
Which stock has performed better over the past year, CRMD or OCS?
CRMD returned -35.05% over the past 12 months, compared with -56.42% for OCS (price return, excluding dividends). Past performance does not predict future results.
Are CorMedix and Oculis in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.